论文部分内容阅读
靛玉红(Indirubin)是治疗慢性粒细胞白血病(以下简称慢粒)中成药“当归芦荟丸”的有效药味青黛的一种成分。中国医学科学院血液学研究所与外单位协作,首次发现靛玉红治疗慢粒有一定疗效。经过五十个医院314例临床观察,总有效率87.3%。1979年12月7日通过卫生部级技术成果鉴定,1981年7月国家科委授予国家发明创造三等奖。现将这项研究工作有关方法学问题讨论如下: 一、选题靛玉红治疗慢粒的选题方法是有一定启示性的。起初,发现当归芦荟丸能够使慢粒缓解,但疗效原理还不清楚。为了寻找新的抗白血病药物,便确定当归芦荟丸治疗慢粒为科研题目。经过十二年研究,取得了靛玉红治疗慢粒的研究成果。从当归芦荟丸治疗慢粒的选题,联想到我国其他中西医结合科研成果的选题,如小夹板治疗骨折、针刺麻醉、活血化瘀中药治疗硬皮病等,都是先从中医治疗疾病的有效
Indirubin (Indirubin) is a component of the effective herbaceous barley in the treatment of chronic myelogenous leukemia (hereinafter referred to as slow-granule) proprietary Chinese medicine “Danggui Aloe Vera Pills.” The Institute of Hematology of the Chinese Academy of Medical Sciences collaborated with an external unit and found for the first time that Diaohong had a certain effect on the treatment of chronic granules. After 314 clinical observations in 50 hospitals, the total effective rate was 87.3%. On December 7, 1979, it passed the appraisal of the Ministry of Health-level technical achievements. In July 1981, the State Science and Technology Commission awarded the third prize for national invention and creation. The methodological issues related to this research work are discussed as follows: I. The selection of the topic for the treatment of chronic granules by Yan Yuhong is instructive. At first, it was found that Angelica Aloe Vera pills can relieve chronic granules, but the principle of efficacy is not yet clear. In order to find new anti-leukemia drugs, it was determined that Angelica Aloe Pills for the treatment of chronic granules was the subject of scientific research. After 12 years of research, we have obtained research results on the treatment of chronic granules by Dai Yuhong. The topic of treatment of chronic granules from Angelica Aloe Vera Pills is associated with the selection of other Chinese and Western medicine research achievements in China, such as small splints for treatment of fractures, acupuncture anesthesia, traditional Chinese medicine for the treatment of scleroderma, etc. Effective disease